Following the new 25m€ loan from EIB, our CEO Tuomas Tenkanen was interviewed to present the latest Mobidiag news and company strategy in the growing market of diagnostics for infectious diseases.
FINLAND Espoo/CHINA, Zhengzhou, June 3 2019 – Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces the launch of Automobi Molecular Diagnostics Co., Ltd (‘Automobi’), the joint venture (‘JV’) between Mobidiag and Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China. Automobi is responsible for commercialising the Novodiag® platform and selected infectious disease assays in the Greater China territory.
EIB Vice-President Alexander Stubb and Tuomas Tenkanen, CEO of Mobidiag (source: EIB)
Investment Plan for Europe: Mobidiag secures EUR 25 million from EIB
- Funds will be used to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases.
- Second operation between the EIB and Mobidiag after first loan in 2016.
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of infectious diseases and antimicrobial resistance, has signed a EUR 25 million growth capital loan with the European Investment Bank (EIB). The EIB loan will be supported by the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe, through the European Growth Finance Facility (EGFF) initiative. This new four-year loan will allow Mobidiag to advance its research and development and facilitate further validation and commercialisation of molecular diagnostics tests on the Company’s Amplidiag® and Novodiag® platforms.
Mobidiag will showcase its fast, reliable and cost-effective molecular diagnostic solutions
Mobidiag Ltd. will be attending the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, the Netherlands, from 13-16 April 2019. Organised by Europe’s leading society in clinical microbiology and infectious diseases, the ECCMID annual meeting brings together leading experts from around the world, including innovative commercial companies specializing in diagnostics.
The publication is now available in the Journal of Clinical Microbiology.
Evaluation of the Amplidiag CarbaR+MCR Kit for Accurate Detection of Carbapenemase-Producing and Colistin-Resistant Bacteria, Delphine Girlich, Sandrine Bernabeu, Victor Grosperrin, Isabelle Langlois, Christine Begasse, Nicolas Arangia, Elodie Creton, Garance Cotellon, Aimie Sauvadet, Laurent Dortet, Thierry Naas, 10.1128/JCM.01800-18
Agreements signed in Greece, Latvia, Lithuania and Kuwait, with more in discussions
Mobidiag Ltd.announced today that it has signed multiple exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with Helix2 for Greece and Interlab INTERAUTOMATIKA UAB for Latvia and Lithuania. Mobidiag has also signed its first agreement in the Middle East with Ibn Rushd Medical & Scientific Equipment Co. for the distribution of Novodiag® in Kuwait. The agreements are effective immediately and initially in place for a period of two years.
Mobidiag Ltd. today announces the completion of the €10m equity investment from Autobio Diagnostics (‘Autobio’), as announced on 18 December 2018, with receipt of all funds.
Proceeds from the €10m equity investment from Autobio will be used by Mobidiag to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system and enhance its manufacturing capabilities, as well as continuing to facilitate Mobidiag’s commercial expansion.
The Novodiag® platform is an innovative molecular diagnostics solution allowing fully automated detection of infectious diseases, including antibiotic resistances. The platform combines real-time PCR and microarray technologies, to allow direct analysis of samples placed in a disposable cartridge. It also allows for comprehensive screening of multiple or single pathogens within approximately one hour, allowing clinicians to be better informed when making time-critical decisions, helping to deliver early treatments and avoid the spread of infection.
Discover a new article in which our CEO Tuomas Tenkanen presents Mobidiag solutions for antibiotic resistance and the recent news in the company.
Mobidiag aims at developing innovative molecular diagnostics for antibiotic resistance – read our CEO’s latest interview on the topic and the company’s future plans.
Read full article in Finnish by clicking here.
Our CEO Tuomas Tenkanen has been interviewed by the Finnish Magazine Talouselämä to talk about the exciting latest news at Mobidiag.
The article features Mobidiag innovative solutions to fight against superbacteria and antibiotic resistances, as well as the latest 10 million euros investment from Chinese company Autobio Diagnostics.
Learn more about the agreement announced last December.
Read full article: in Finnish, in English.
CE-IVD marking of Novodiag® CarbaR+, the 3rd molecular test on the automated system Novodiag®, for detection of the main Carbapenemase-Producing Enterobacteriaceae (CPE) and colistin resistance markers in one single test.
ESPOO, Finland, January 7th, 2019 – Mobidiag Ltd. today announces the CE-IVD marking of Novodiag® CarbaR+. Novodiag® CarbaR+ is a single molecular test allowing fully automated detection of Carbapenemase-Producing Enterobacteriaceae (CPE), and associated resistance markers. CPE are bacteria that are resistant to carbapenem class of antibiotics. In addition, Novodiag® CarbaR+ identifies a plasmid-mediated resistance to colistin. Colistin is considered the drug of last resort for many infections.